MiR-98 regulates cisplatin-induced A549 cell death by inhibiting TP53 pathway

Biomedicine and Pharmacotherapy

Volumn 65, Issue 6, 2011, Pages 436-442

  Zhang, Shuai ^a   Zhang, Chao ^a   Li, Youjie ^a   Wang, Pingyu ^a   Yue, Zhen ^a   Xie, Shuyang ^a  

^a Binzhou Medical University   (China)

Author keywords

Bcl 2; Gene expression; Lung cancer; MicroRNAs; TP53

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; MICRORNA; MICRORNA 98; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL DEATH; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG CANCER; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DOWN-REGULATION; GENES, P53; GENES, REPORTER; HUMANS; LUNG NEOPLASMS; MICRORNAS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SOFTWARE;

EID: 80052660944     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.04.010     Document Type: Article

References (46)

1. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E., et al. Cancer statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
2. Williams M.D., Sandler A.B. The epidemiology of lung cancer. Cancer Treat Res 2001, 105:31-52.
3. July L.V., Beraldi E., So A., Fazli L., Evans K., English J.C., et al. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 2004, 3:223-232.
4. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
5. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 2007, 26:2145-2156.
6. Danesi R., de Braud F., Fogli S., de Pas T.M., Di Paolo A., Curigliano G., et al. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003, 55:57-103.
7. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003, 10:431-442.
8. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992, 89:7491-7495.
9. Smith F.M., Stephens R.B., Kennedy M.J., Reynolds J.V. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005, 92:1813.
10. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991, 51:6304-6311.
11. Lane D.P. Cancer. A death in the life of p53. Nature 1993, 362:786-787.
12. Spurgers K.B., Gold D.L., Coombes K.R., Bohnenstiehl N.L., Mullins B., Meyn R.E., et al. Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression. J Biol Chem 2006, 281:25134-25142.
13. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
14. Bhattacharyya S.N., Habermacher R., Martine U., Closs E.I., Filipowicz W. Stress-induced reversal of microRNA repression and mRNA P-body localization in human cells. Cold Spring Harb Symp Quant Biol 2006, 71:513-521.
15. Iorio M.V., Ferracin M., Liu C.G., Veronese A., Spizzo R., Sabbioni S., et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070.
16. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006, 103:2257-2261.
17. Akao Y., Nakagawa Y., Naoe T. MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncol Rep 2006, 16:845-850.
18. Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004, 101:2999-3004.
19. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007, 17:1298-1307.
20. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007, 26:745-752.
21. Corney D.C., Flesken-Nikitin A., Godwin A.K., Wang W., Nikitin A.Y. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007, 67:8433-8438.
22. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., et al. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
23. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 2007, 26:731-743.
24. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A 2007, 104:15472-15477.
25. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PloS One 2009, 4:e6816.
26. Zenz T., Mohr J., Eldering E., Kater A.P., Bühler A., Kienle D., et al. miR-34a as part of the resistance network in chronic lymphocytic leukemia. Blood 2009, 113:3801-3808.
27. Ji Q., Hao X., Meng Y., Zhang M., Desano J., Fan D., et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 2008, 8:266.
28. Fan T., Li R., Todd N.W., Qiu Q., Fang H.B., Wang H., et al. Up-regulation of 14-3-3zeta in lung cancer and its implication as prognostic and therapeutic target. Cancer Res 2007, 67:7901-7906.
29. Videhult P., Yachnin J., Jerremalm E., Lewensohn R., Ehrsson H. Synthesis and cytotoxicity of the dihydrated complex of oxaliplatin. Cancer Lett 2002, 180:191-194.
30. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
31. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
32. Du T., Zamore P.D. microPrimer: the biogenesis and function of microRNA. Development 2005, 132:4645-4652.
33. el-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993, 75:817-825.
34. Hermeking H., Lengauer C., Polyak K., He T.C., Zhang L., Thiagalingam S., et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997, 1:3-11.
35. Yu J., Zhang L., Hwang P.M., Kinzler K.W., Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001, 7:673-682.
36. Du L., Schageman J.J., Subauste M.C., Saber B., Hammond S.M., Prudkin L., et al. miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res 2009, 7:1234-1243.
37. Hebert C., Norris K., Scheper M.A., Nikitakis N., Sauk J.J. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer 2007, 6:5.
38. Sarhadi V.K., Wikman H., Salmenkivi K., Kuosma E., Sioris T., Salo J., et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006, 209:206-212.
39. Sgarra R., Rustighi A., Tessari M.A., Di Bernardo J., Altamura S., Fusco A., et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004, 574:1-8.
40. Boo L.M., Lin H.H., Chung V., Zhou B., Louie S.G., O'Reilly M.A., et al. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 2005, 65:6622-6630.
41. Dedoussis G.V., Mouzaki A., Theodoropoulou M., Menounos P., Kyrtsonis M.C., Karameris A., et al. Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line. Exp Cell Res 1999, 249:269-278.
42. Hasinoff B.B., Wu X., Yang Y. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). J Inorg Biochem 2004, 98:616-624.
43. Bhatt K., Zhou L., Mi Q.S., Huang S., She J.X., Dong Z. MicroRNA-34a Is Induced via p53 during cisplatin nephrotoxicity and contributes to Cell Survival. Mol Med 2010, 16:409-416.
44. Yu Z.W., Zhong L.P., Ji T., Zhang P., Chen W.T., Zhang C.P. MicroRNAs contribute to the chemoresistance of cisplatin in tongue squamous cell carcinoma lines. Oral Oncol 2010, 46:317-322.
45. Xie S.Y., Li Y.J., Wang P.Y., Jiao F., Zhang S., Zhang W.J. miRNA-regulated expression of oncogenes and tumor suppressor genes in the cisplatin-inhibited growth of K562 cells. Oncol Rep 2010, 23:1693-1700.
46. Galluzzi L., Morselli E., Vitale I., Kepp O., Senovilla L., Criollo A., et al. miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 2010, 70:1793-1803.